ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab Data Have Been Accepted as E-Posters at the 31st European Academy of Dermatology and Venereology (EADV) Congress

Rhea-AI Summary

ASLAN Pharmaceuticals (NASDAQ: ASLN) announced the presentation of three abstracts on eblasakimab at the 31st European Academy of Dermatology and Venereology Congress from September 7-10, 2022. These findings highlight eblasakimab's efficacy in treating moderate-to-severe atopic dermatitis in adult patients through randomized, double-blinded studies. The posters will address improvements in disease measures, reduction in biomarkers associated with atopy, and alleviation of itch and sleep disturbances.

Positive

• Three abstracts showcasing eblasakimab's efficacy will be presented at a major dermatology congress.
• Studies demonstrate eblasakimab's potential to improve disease measures in patients with moderate-to-severe atopic dermatitis.

Negative

• None.

MENLO PARK, Calif. and SINGAPORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that three abstracts, showcasing new findings related to eblasakimab, will be displayed as e-posters throughout the 31st European Academy of Dermatology and Venereology (EADV) Congress, to be held in-person and virtually from September 7 to 10, 2022, in Milan, Italy.

31st European Academy of Dermatology and Venereology Congress e-poster details

Poster 1: Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study
(abstract ID: #2464, poster ID:   P0343)

Poster 2: Eblasakimab, a monoclonal antibody targeting IL-13Ra1, reduces serum biomarkers that are associated with atopy and correlated with disease severity, in patients with moderate-to-severe atopic dermatitis
(abstract ID: #932, poster ID: P0243)

Poster 3: Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study
(abstract ID: #2459, poster ID:   P0342)

Poster availability date and time: Wednesday, September 7 to 10, 2022.

Location: MiCo Milano Convention Center, e-poster area and online

The posters will be available to view online in the Investor Relations section of ASLAN’s website following presentation: https://ir.aslanpharma.com/.

About eblasakimab

Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor, with the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen for atopic dermatitis patients. In September 2021, ASLAN announced positive results from the Phase 1b multiple-ascending-dose study that established proof-of-concept of ASLAN004 and supported its potential as a novel treatment for AD. In January 2022, ASLAN initiated the TREK-AD Phase 2b trial to evaluate the safety and efficacy of eblasakimab in moderate-to-severe AD patients.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab (also known as ASLAN004), a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat (also known as ASLAN003), a potent oral inhibitor of the enzyme DHODH, in autoimmune disease. ASLAN has a team in California and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.

Media and IR contacts

Emma Thompson  Spurwing Communications  Tel: +65 6206 7350  Email: ASLAN@spurwingcomms.com

Ashley R. Robinson  LifeSci Advisors, LLC  Tel: +1 (617) 430-7577   Email: arr@lifesciadvisors.com

 

FAQ

What findings are being presented about eblasakimab at the EADV Congress?

The presented findings showcase eblasakimab's efficacy in improving disease measures, reducing biomarkers related to atopy, and alleviating symptoms in patients with moderate-to-severe atopic dermatitis.

When will the eblasakimab posters be available for viewing?

The posters will be available for viewing from September 7 to 10, 2022.

Where can I find more information about ASLAN Pharmaceuticals' eblasakimab?

Additional information about eblasakimab can be found on ASLAN Pharmaceuticals' Investor Relations website after the presentation.

What is the significance of eblasakimab in treating atopic dermatitis?

Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor, aiming to provide a differentiated safety and efficacy profile for atopic dermatitis patients.